RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus
GSK plans to acquire RAPT Therapeutics for $58 per share in cash, valuing the biotech at $2.2 billion. RAPT stock traded around $57.60 Wednesday, about 40 cents below the offer. The deal includes a tender offer expected within 10 business days and is subject to antitrust review. The merger is expected to close in Q1 2026.